Jpmorgan Chase & CO Neogenomics Inc Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Neogenomics Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 287,543 shares of NEO stock, worth $2.09 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
287,543
Previous 607,332
52.65%
Holding current value
$2.09 Million
Previous $10 Million
72.74%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding NEO
# of Institutions
288Shares Held
127MCall Options Held
942KPut Options Held
172K-
Black Rock Inc. New York, NY19.7MShares$143 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.3MShares$104 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny6.72MShares$48.9 Million0.04% of portfolio
-
First Light Asset Management, LLC Edina, MN6.04MShares$44 Million7.36% of portfolio
-
Janus Henderson Group PLC London, X05.74MShares$41.8 Million0.03% of portfolio
About NEOGENOMICS INC
- Ticker NEO
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 125,796,000
- Market Cap $916M
- Description
- NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytoge...